Abstract
The leucine-rich repeat kinase 2 (LRRK2) gene and α-synuclein gene (SNCA) are the key influencing factors of Parkinson’s disease (PD). It is reported that dysfunction of LRRK2 may influence the accumulation of α-synuclein and its pathology to alter cellular functions and signaling pathways by the kinase activation of LRRK2. The accumulation of α-synuclein is one of the main stimulants of microglial activation. Microglia are macrophages that reside in the brain, and activation of microglia is believed to contribute to neuroinflammation and neuronal death in PD. Therefore, clarifying the complex relationship among LRRK2, α-synuclein and microglials could offer targeted clinical therapies for PD. Here, we provide an updated review focused on the discussion of the evidence supporting some of the key mechanisms that are important for LRRK2-dependent neurodegeneration in PD.
Keywords: Leucine-rich repeat kinase 2, MAPK, α-synuclein, neurodegeneration, neuroinflammation, microglia, Parkinson`s disease.
Graphical Abstract
Current Neuropharmacology
Title:The Role of LRRK2 in Neurodegeneration of Parkinson Disease
Volume: 16 Issue: 9
Author(s): Qin Rui, Haibo Ni, Di Li, Rong Gao*Gang Chen
Affiliation:
- Department of Neurosurgery, The First People`s Hospital of Zhangjiagang City, Suzhou, Jiangsu,China
Keywords: Leucine-rich repeat kinase 2, MAPK, α-synuclein, neurodegeneration, neuroinflammation, microglia, Parkinson`s disease.
Abstract: The leucine-rich repeat kinase 2 (LRRK2) gene and α-synuclein gene (SNCA) are the key influencing factors of Parkinson’s disease (PD). It is reported that dysfunction of LRRK2 may influence the accumulation of α-synuclein and its pathology to alter cellular functions and signaling pathways by the kinase activation of LRRK2. The accumulation of α-synuclein is one of the main stimulants of microglial activation. Microglia are macrophages that reside in the brain, and activation of microglia is believed to contribute to neuroinflammation and neuronal death in PD. Therefore, clarifying the complex relationship among LRRK2, α-synuclein and microglials could offer targeted clinical therapies for PD. Here, we provide an updated review focused on the discussion of the evidence supporting some of the key mechanisms that are important for LRRK2-dependent neurodegeneration in PD.
Export Options
About this article
Cite this article as:
Rui Qin , Ni Haibo, Li Di , Gao Rong *, Chen Gang, The Role of LRRK2 in Neurodegeneration of Parkinson Disease, Current Neuropharmacology 2018; 16 (9) . https://dx.doi.org/10.2174/1570159X16666180222165418
DOI https://dx.doi.org/10.2174/1570159X16666180222165418 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy Towards the Development of Tumor Necrosis Factor (TNF) Sensitizers:Making TNF Work Against Cancer
Current Pharmaceutical Design Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Editorial from Guest Editor (DNA Methylation: A Target for Current and Future Therapies?)
Epigenetic Diagnosis & Therapy (Discontinued) PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology Malignant Glioma In Vitro Models: On the Utilization of Stem-like Cells
Current Cancer Drug Targets Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging Recent Developments in Boron Neutron Capture Therapy (BNCT) Driven by Nanotechnology
Current Chemical Biology TGF-Beta: a Master Switch in Tumor Immunity
Current Pharmaceutical Design Pharmacophores for Ligand Recognition and Activation / Inactivation of the Cannabinoid Receptors
Current Pharmaceutical Design Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moeities
Mini-Reviews in Medicinal Chemistry Nanoparticle-based Drug Delivery Systems for Solid Brain Tumors
Current Nanoscience Innate Immune Receptors and IRF Family Transcription Factors
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Interest of Folic Acid in Targeted Photodynamic Therapy
Current Medicinal Chemistry Salvage Hypofractionated Radiotherapy in Combination with Bevacizumab in Patients with Recurrent High Grade Glioma: A Mono-institutional Experience
Clinical Cancer Drugs Toll-Like Receptors: Cost or Benefit for Cancer?
Current Pharmaceutical Design Hypoxia in DU-145 Prostate Cancer Xenografts after Estramustine Phosphate and Radiotherapy
Current Radiopharmaceuticals The Association between Tumor-associated Macrophages and Glioblastoma: A Potential Target for Therapy
Current Pharmaceutical Design